Financial calendar for BerGenBio ASA
FINANCIAL YEAR 2020
10.02.2021 - Quarterly Report - Q4
FINANCIAL YEAR 2021
17.08.2021 - Half-yearly Report
25.02.2021 - Annual Report
19.03.2021 - Annual General Meeting
19.05.2021 - Quarterly Report - Q1
16.11.2021 - Quarterly Report - Q3
The dates are subject to change. The time and location of the presentations will
be announced in due time.
For more information, please contact:
ir@bergenbio.com
or visit www.bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
This information is published pursuant to the requirements set out in the Continuing obligations.